---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-057710"
form_type: "8-K"
ticker: "NTRA"
cik: "0001604821"
company_name: "Natera, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:12:54.056148+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Natera Q1 revenue $241.8M (+24.5% YoY), raises 2023 revenue guidance to $995M-$1.015B

## Summary
- Total revenue $241.8M (+24.5% YoY); product revenue $237.8M (+25.2% YoY).
- Tests processed 626,200 (+28% YoY); oncology tests 71,000 (+102% YoY).
- Net loss $136.9M ($1.23/share) vs $138.6M ($1.45) in prior year; loss per share improved.
- Raised 2023 revenue guidance to $995M-$1.015B from prior $990M-$1.0B; gross margin guidance unchanged at 41%-44%.
- Secured Medicare coverage for Prospera heart transplant test and first commercial coverage for Signatera (Blue Shield CA).

## SEC filing metadata
- accession: 0001104659-23-057710
- form_type: 8-K
- ticker: NTRA
- cik: 0001604821
- company_name: Natera, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604821/000110465923057710/0001104659-23-057710-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604821/000110465923057710/tm2314862d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-057710
- JSON: https://secwatch.observer/filing/0001104659-23-057710.json
- Plain text: https://secwatch.observer/filing/0001104659-23-057710.txt

## Key facts
- Earnings Releases
  Natera, Inc. reported first quarter ended March 31, 2023 results: revenue $241.8 million, net income net loss of $136.9 million, EPS ($1.23) per diluted share. Guidance raised.
  - Period: first quarter ended March 31, 2023
  - Revenue: $241.8 million
  - Net income: net loss of $136.9 million
  - EPS: ($1.23) per diluted share
  - Guidance: raised
  - Result: reported results
  source text: in cell-free DNA testing , today reported financial results for the first quarter ended March 31, 2023. Recent Strategic and Financial Highlights ● Generated total revenues of $241.8 million in the first quarter of 2023, compared to $194.1 million in the first quarter of 2022, an increase of 24.5%. Product revenues grew 25.2% over the same period. ● Processed
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604821/000110465923057710/0001104659-23-057710-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.